Comparative Pharmacology
Head-to-head clinical analysis: CHOLOVUE versus DIATRIZOATE 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOVUE versus DIATRIZOATE 60.
CHOLOVUE vs DIATRIZOATE-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
Diatrizoate is an ionic, monomeric, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, enhancing radiographic imaging by attenuating X-ray beams. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
1-2 mL/kg IV bolus up to 150 mL total for contrast-enhanced CT; repeat doses may be given based on imaging needs.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
Terminal half-life approximately 1-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 20-30 hours in anuria).
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Negligible biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent